Femasys Inc is a healthcare company focused on developing innovative products and solutions to enhance women's reproductive health
The company aims to address unmet medical needs in areas such as fertility and contraception through advanced medical technologies. Femasys is committed to improving patient outcomes by offering minimally invasive and user-friendly procedures, thereby empowering women with more options for their reproductive health management. Their research and development efforts are geared toward creating safer, effective, and cost-efficient treatments that can be accessible to a broader audience.
European patents expand coverage for both essential components of FemBloc for fallopian tube occlusion, resulting in non-surgical permanent contraception
Trial results demonstrated safety and effectiveness of FemaSeed intratubal insemination with high satisfaction ratings from both practitioners and patients
ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at Maxim Group. The summit is being held virtually on October 15 – 17, 2024.
ATLANTA, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company has received its second order from its strategic distribution partners after successfully completing its first commercial FemaSeed® procedures in Europe. Members of the Femasys team traveled to Madrid to in-service healthcare practitioners on the innovative FemaSeed infertility treatment, designed to enhance natural fertilization by precisely delivering sperm into the fallopian tube where conception occurs.
In addition to 510(k) clearance, FemChec, a contrast generating product, is an integral part of the confirmation test following administration of FemBloc non-surgical permanent birth control, currently in late-stage pivotal trial
ATLANTA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the Canadian Fertility and Andrology Society’s (CFAS) 70th Annual Meeting, to be held September 12-14, 2024 at The Westin Bayshore, Vancouver, British Columbia. The Company will be exhibiting at Booth #S26.
ATLANTA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference. The fireside chat will be hosted by Emily Bodnar, Life Sciences Analyst. The conference is being held on September 9 – 11, 2024 at the Lotte New York Palace Hotel.
ATLANTA, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQFEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products, announces that it has received CE mark certification and product approval from Health Canada, the Public Health Agency of Canada, for its compact, eco-friendly FemVue® MINI for fallopian tube assessment.
The Congresswoman representing Georgia’s 7th district in the U.S. House of Representatives toured Femasys’ facilities to gain a better understanding of our advancements for women’s reproductive health
SUWANEE, GA / ACCESSWIRE / August 19, 2024 / Femasys Inc. (NASDAQFEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible and innovative therapeutic and diagnostic products. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
